{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:38:31Z","timestamp":1786113511696,"version":"build-2736575974"},"reference-count":40,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2007,1,1]]},"DOI":"10.1080\/10428190601158639","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T15:20:17Z","timestamp":1180020017000},"page":"683-690","source":"Crossref","is-referenced-by-count":32,"title":["Phase I trial of\n                    <sup>90<\/sup>\n                    Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation"],"prefix":"10.1080","volume":"48","author":[{"given":"Julie M.","family":"Vose","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Bierman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Fausto R.","family":"Loberiza","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Bociek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Matso","sequence":"additional","affiliation":[{"name":"Biogen Idec, Inc., San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O.","family":"Armitage","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2009,7,1]]},"reference":[{"key":"e_1_3_1_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.423"},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.406"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3911"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3776"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3837"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.12.2351"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3264"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.054"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0982"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.023"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704214"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00481.x"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.8.2142.2142"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703888"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.055"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.015"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3883"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.040"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2004.19.478"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.6.1316"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.9217"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2005.20.185"},{"key":"e_1_3_1_26_1","volume-title":"Zevalin (Ibritumomab Tiuxetan) Prescribing Information","year":"2005","unstructured":"Zevalin (Ibritumomab Tiuxetan) Prescribing Information. Biogen Idec, Cambridge, MA 2005"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1004-0003"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1259"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"e_1_3_1_32_1","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2002.v8.pm12434949"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh425"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.012"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500376076"},{"key":"e_1_3_1_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.6561"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"e_1_3_1_39_1","first-page":"579s","article-title":"Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: update of a Minnie Pearl Cancer Research Network phase II trial (Abstract 6577)","volume":"23","author":"Shipley D L","year":"2005","unstructured":"Shipley D L, Greco F A, Spigel D R, Edwards D, Mayfield M, Yost K. Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: update of a Minnie Pearl Cancer Research Network phase II trial (Abstract 6577). Proc Am Soc Clin Oncol 2005; 23: 579s","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.2633.2633"},{"key":"e_1_3_1_41_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.028"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428190601158639","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/10428190601158639","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428190601158639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T19:38:31Z","timestamp":1785958711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428190601158639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,1,1]]}},"alternative-id":["10.1080\/10428190601158639"],"URL":"https:\/\/doi.org\/10.1080\/10428190601158639","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,1]]}}}